Biotech major Biocon Ltd reported a consolidated net profit of Rs 214 crore for the fourth quarter of fiscal 2018-19, registering 64 percent annual growth from Rs 130 crore in the same period a year ago. For the fiscal, the consolidated net profit shot up 143 percent annually to Rs 905 crore from Rs 372 crore a year ago in fiscal 2017-18. In a regulatory filing on the BSE, the city-based firm said that consolidated revenue from operations for the quarter (Q4) under review grew 31 percent annually to Rs 1,529 crore from Rs 1,170 crore in the same period a year ago.

For the fiscal under review, Ebitda grew 49 percent YoY to Rs 1,538 crore from Rs 1,035 crore in the previous fiscal. “Our quarterly performance was led by robust growth in biologics and research services segments, supported by growth in small molecules segment,” Biocon Chairperson Kiran Mazumdar-Shaw in a statement.